- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
New Research Highlights Emerging MRI Contrast Agent for Bladder Imaging
A new MRI contrast agent may provide a viable non-invasive alternative for the detection of interstitial cystitis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
Through intravesical contrast-enhanced MRI (ICE-MRI), the dual-component MRI contrast agent LP-20 facilitated enhanced phenotyping differentiation between bladder-centric interstitial cystitis (IC) and endometriosis, according to preliminary research presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ) in Kyoto, Japan.
Researchers found that T1- and T2-weighted ICE-MRI images with LP-20 (Lipella Pharmaceuticals) enabled a wider field of view for pelvic abnormalities as well as visualization of sub-surface lesion depth and wall thickening on the serosal side of the bladder that one cannot see via cystoscopy.
The images reveal greater than 7 mm of bladder wall thickening and luminal side trabeculations for a 69-year-old patient with a urethelial lesion (A and C). A sagittal view for a 35-year-old patient revealed a bladder wall less than 5 mm in thickness. (Images courtesy of the 5th International Consultation on Interstitial Cystitis Japan (ICICJ)).
Designed for interstitial cystitis detection, the LP-20 agent may also facilitate the diagnosis of bladder pain syndrome (BPS), according to Lipella Pharmaceuticals.
“LP-20 provides a valuable tool for phenotyping IC/BPS, potentially streamlining patient identification for clinical trials and improving timely access to effective treatments,” added lead study author Pradeep Tyagi, M.D., an associate professor in the Department of Urology at the University of Pittsburgh Medical Center.
The company added that LP-20, which has been the subject of completed pre-clinical and proof-of-concept human trial research, can also diagnose the progression of bladder cancer to muscle invasive bladder cancer.
References
1. Chancellor M, Moon CH, Chermansky C, Yoshimura N, Kaufman J, Tyagi P. Size-dependent paracellular diffusion into urothelium is embodied by intravesical contrast enhanced magnetic resonance imaging (ICE-MRI). Presented at the 5th International Consultation on Interstitial Cystitis Japan (ICICJ), August 21-23, Kyoto, Japan.
2. Lipella Pharmaceuticals. Lipella Pharmaceuticals unveils advanced bladder imaging technique at ICICJ conference. BioSpace. Available at https://www.biospace.com/lipella-pharmaceuticals-unveils-advanced-bladder-imaging-technique-at-icicj-conference . Published August 21, 2024. Accessed August 21, 2024.
MRI or Ultrasound for Evaluating Pelvic Endometriosis?: Seven Takeaways from a New Literature Review
September 13th 2024While noting the strength of MRI for complete staging of disease and ultrasound’s ability to provide local disease characterization, the authors of a new literature review suggest the two modalities offer comparable results for diagnosing pelvic endometriosis.
Diffusion-Weighted MRI and Neoadjuvant Chemotherapy for Rectal Cancer: What New Research Reveals
September 3rd 2024In a comparison of imaging assessments to gauge the effectiveness of neoadjuvant chemotherapy for rectal adenocarcinoma, researchers found the combination of diffusion-weighted imaging and MR tumor regression grading had a 90 percent area under the curve (AUC) and a negative predictive value (NPV) of 93 percent.
FDA Expands Clearance of MRI-Guided AI Platform for Deep Brain Stimulation and Lesioning Techniques
September 3rd 2024Utilizing a new machine learning model, the OptimMRI software may improve radiosurgery applications and lesioning techniques such as MRI-guided focused ultrasound through enhanced targeting of the inferolateral part of the ventral intermediate nucleus (VIM).
